Calidi Biotherapeutics, Inc.
CLDI
$1.49
-$0.01-0.73%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.50% | 16.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.88% | 11.89% | |||
| Operating Income | 10.88% | -11.89% | |||
| Income Before Tax | 10.18% | -13.80% | |||
| Income Tax Expenses | 150.00% | 33.33% | |||
| Earnings from Continuing Operations | 10.07% | -13.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -30.43% | -39.47% | |||
| Net Income | 9.90% | -14.62% | |||
| EBIT | 10.88% | -11.89% | |||
| EBITDA | 0.31% | 0.34% | |||
| EPS Basic | -11.02% | 10.08% | |||
| Normalized Basic EPS | 47.19% | 9.69% | |||
| EPS Diluted | -11.02% | 10.08% | |||
| Normalized Diluted EPS | 47.19% | 9.69% | |||
| Average Basic Shares Outstanding | 70.56% | 27.46% | |||
| Average Diluted Shares Outstanding | 70.56% | 27.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||